Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE)
|ClinicalTrials.gov Identifier: NCT00330863|
Recruitment Status : Completed
First Posted : May 29, 2006
Last Update Posted : July 15, 2014
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia Schizoaffective Disorder||Drug: Risperidone microspheres Drug: Risperidone Drug: Olanzapine Drug: Quetiapine Drug: Ziprasidone Drug: Aripiprazole Drug: Paliperidone||Phase 4|
As is the case with many chronic illnesses, it can be challenging for people with schizophrenia to take multiple pills every day on a long-term basis. At the same time, missing or discontinuing the anti-psychotic medications that treat schizophrenia substantially increases the risk of relapse and re-hospitalization. This study will determine how effective long-acting injectable risperidone is compared to oral antipsychotic medications to help patients who have schizophrenia. Patients who enroll in the study will be randomly assigned to receive either long-acting injectable risperidone or to receive oral "atypical" antipsychotic medication. The "atypical" antipsychotics that are included for patients in the oral group are: aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone. Patients in the "oral" group will receive whichever of the five "atypical" antipsychotic medications they and their study doctor decide is best for them. Patients in the "oral" group will be allowed to switch to others of the five medications during the study if they and their doctor think that is best.
Patients in this study will be evaluated at the beginning of the study and then again every two weeks for up to 30 months (2 1/2 years). Each two-week visit will take about 20 minutes. At the visit, patients will receive medication and will be examined for side effects of the medications, their vital signs (heart rate, blood pressure, weight, and waist measurement) will be measured, and they will be asked a few questions about attendance at visits and taking medication. The visit that occurs every three months will take about one hour, instead of 20 minutes, and will include additional questions, an examination for muscle stiffness or abnormal body movements, and an interview from a member of the research team conducted using computer technology. In addition, blood and urine samples may be collected about seven times throughout the 30 months of the study treatment. Patients who enroll in this study after the halfway point of the study, may not receive a full 30 months of treatment, but it is planned that all patients will have the opportunity to receive no less than 18 months of treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||357 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE)|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||January 2011|
Participants assigned to receive long-acting injectable risperidone
Drug: Risperidone microspheres
Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
Other Name: Risperdal Consta
Active Comparator: Oral
Participants assigned to receive oral "atypical" antipsychotic medication
Target dose is 4 mg/day.
Other Name: Risperdal
Target dose is 15 mg/day.
Other Name: Zyprexa
Target dose is 600 mg/day.
Other Name: Seroquel
Target dose is 120 mg/day.
Other Name: Geodon
Target dose is 20 mg/day.
Other Name: Abilify
Target dose is 6 mg/day.
Other Name: Invega
- Time to relapse, where "relapse" is defined as psychiatric hospitalization [ Time Frame: Measured throughout study ]
- Increase in the level of psychiatric care required to avert hospitalization [ Time Frame: Measured throughout study ]
- Substantial clinical deterioration measured by psychotic symptoms [ Time Frame: Measured throughout study ]
- Number of patients discontinuing from the study [ Time Frame: Measured throughout study ]
- Number of days in hospital [ Time Frame: Measured throughout study ]
- Visits to hospital emergency rooms [ Time Frame: Measured throughout study ]
- Control of psychiatric symptoms [ Time Frame: Measured throughout study ]
- Quality of life measures [ Time Frame: Measured throughout study ]
- Side effects and metabolic measures [ Time Frame: Measured throughout study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00330863
|United States, California|
|University of California, Los Angeles|
|Los Angeles, California, United States, 91344|
|United States, Georgia|
|Medical College of Georgia, Department of Psychiatry|
|Augusta, Georgia, United States, 30912-3800|
|United States, Iowa|
|University of Iowa College of Medicine, Psychiatry Research|
|Iowa City, Iowa, United States, 52242|
|United States, Massachusetts|
|Harvard Medical School -- Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Harvard Medical School -- Dr. John C. Corrigan Community Mental Health Center|
|Fall River, Massachusetts, United States, 02720|
|United States, Nebraska|
|Omaha, Nebraska, United States, 68131|
|United States, New Mexico|
|University of New Mexico|
|Albuquerque, New Mexico, United States, 87131|
|United States, New York|
|The Zucker Hillside Hospital|
|Glen Oaks, New York, United States, 11004|
|Study Director:||Nina R. Schooler, PhD||Steering and Implementation Center|